debt_leverage_profile
Low debt; HUTCHMED holds ~$500M+ cash with minimal long-term debt, net cash positive; 20% rate rise immaterial to operations
Inferred
Agent_Inference
interest_rate_sensitivity
Minimal; company is net cash positive with limited floating-rate debt exposure; higher rates modestly boost cash income on reserves
Inferred
Agent_Inference
geopolitical_supply_exposure
Low intensity; China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
supply_chain_dependency
China API/raw material sourcing for oncology drugs; US-China tech/export control restrictions on biologics ingredients and lab equipment
Inferred
Agent_Inference
international_expansion_readiness
Primary markets: USD (US), EUR (Europe), CNY (China); CNY devaluation risk is significant given ~50%+ China revenue base
Inferred
Agent_Inference
geographic_footprint
China (~50% revenue), US, Europe; CNY devaluation materially impacts reported USD results; USD/EUR markets provide partial natural hedge
Inferred
Agent_Inference
commodity_exposure_profile
Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
vendor_lock_dependency_score
No single vendor >30% of inputs; however, CROs and CMOs in China are critical; moderate substitutability risk for specialized biologics manufacturing
Inferred
Agent_Inference
business_model_type_primary
Biopharmaceutical drug developer and commercializer; not cloud-dependent for core revenue; cloud disruption would affect back-office, not drug sales
Inferred
Agent_Inference
business_model_type_secondary
Partnership/licensing model with AstraZeneca for global commercialization; cloud termination poses minimal direct revenue risk
Inferred
Agent_Inference
switching_cost_profile
Low API coupling risk; not a software platform; clinical data systems could migrate within 60-90 days with moderate disruption
Inferred
Agent_Inference
howey_test_risk_index
Low Howey risk; revenue from drug sales and licensing fees, not investment contracts; equity shares are conventional securities
Inferred
Agent_Inference
regulatory_burden_tier
Very High
Medium
GICS-regulatory-overlay-v1
data_sovereignty_risk
Moderate; clinical trial data held in China subject to PIPL; US/EU patient data requires GDPR/HIPAA compliance for expanding trials
Inferred
Agent_Inference
antitrust_exposure_flag
Low antitrust risk; niche oncology focus, no dominant market share; operates in competitive multi-player immuno-oncology market
Inferred
Agent_Inference
regulatory_exposure_profile
Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.
Medium
GICS-regulatory-overlay-v1
revenue_model_type
Predominantly transactional/milestone-based; drug sales revenue plus licensing milestones; recurring royalty streams growing but <30% of total revenue
Inferred
Agent_Inference
monetization_vector
Drug product sales (China commercial) + licensing/collaboration fees from AstraZeneca and partners + royalties on out-licensed assets
Inferred
Agent_Inference
pricing_architecture
Oncology drug pricing in China subject to NRDL negotiation pressure; US/EU pricing has higher ceiling but reimbursement risk; margin compression likely in China
Inferred
Agent_Inference
pricing_power_rating
Moderate; differentiated oncology assets (fruquintinib, savolitinib) provide pricing leverage, but Chinese NRDL inclusion requires steep discounts
Inferred
Agent_Inference
target_gross_margin_bracket
Product gross margin ~60-75%; blended margin lower due to R&D burn; targeting pharma-typical 70%+ gross margin at commercial scale
Inferred
Agent_Inference
churn_vulnerability_index
No free-rider problem; prescription drugs require physician/hospital purchasing; patient assistance programs are bounded cost, not leakage
Inferred
Agent_Inference
headcount_cost_structure
Moderately headcount-linear; commercial expansion in China requires sales force scaling; R&D headcount tied to pipeline stage count
Inferred
Agent_Inference
marginal_cost_of_growth
Sublinear at mature commercial stage; existing manufacturing and sales infrastructure supports revenue growth with <proportional headcount additions
Inferred
Agent_Inference
franchise_compliance_risk
Not applicable; not a franchise business model
Inferred
Agent_Inference
customer_acquisition_metric
At 10x scale: hospital formulary access and physician detailing remain key; CAC rises with geographic expansion but LTV improves with chronic-use oncology drugs
Inferred
Agent_Inference
network_effect_present
No meaningful network effects; drug efficacy and physician relationships drive adoption, not user-base size
Inferred
Agent_Inference
asset_efficiency_ratio
AI can accelerate trial design and biomarker analysis; moderate displacement risk in data science roles; core lab/clinical execution remains human-dependent
Inferred
Agent_Inference
recession_resistance_tier
High recession resistance; oncology drugs are non-discretionary; patient volumes relatively stable across economic cycles
Inferred
Agent_Inference
customer_segment_primary
Hospitals and oncology centers in China; top-tier hospitals represent significant concentration in early commercial rollout
Inferred
Agent_Inference
customer_segment_secondary
Global pharma partners (AstraZeneca primary); single-partner concentration risk for ex-China licensing revenue is meaningful
Inferred
Agent_Inference
characteristic_occupations
["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]
High
SOC-2018/GICS-overlay
agent_automatable_labor_share
0.32 (HIL — ~32% of characteristic roles agent-automatable)
Medium
SOC-2018 + agentic-exposure-v1
capital_expenditure_profile
Capital shifting from R&D-heavy pipeline investment toward commercial infrastructure; some legacy trial spending winds down as assets reach approval
Inferred
Agent_Inference
sec_cik
0001648257
High
SEC-EDGAR
ticker
HCM
High
SEC-EDGAR